Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Meaning: The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand effects on other clinically relevant outcomes.
https://jamanetwork.com/journals/jama/fullarticle/2777389
About Mabs said this new earlier today,
Regeneron ****tail Stumbles Against SARS-CoV-2 Variant in Vitro
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
https://www.the-scientist.com/news-opinion/regeneron-****tail-stumbles-against-sars-cov-2-variant-in-vitro-68503
TipTop09 just shared the first 1/4 of the article, the full article is here.
https://www.reddit.com/r/synairgen/comments/lwyjyc/synairgen_an_investment_brief_by_rupert_marlow/?utm_source=share&utm_medium=web2x&context=3
Can someone clear something up for me regarding the IP. From the above clearly the formulation is patented, but my understanding was that the IP covered the use of interferon beta generally in nebulised/inhaled use for certain viral infections. Is this correct ?
ie its the indication, not just the formulation that is covered, and that these are independent of one another.
thanks
I think this is a more updated vision of the doc someone shared a few days ago, https://fnih.org/sites/default/files/final/pdf/Protocol-activ-2-A5401-version3-dated12.22.20.pdf
''Interferon-beta won’t be the magic formula to cure long COVID for good, but it’s a much-needed treatment that can help save lives.''
you never know if Interferon-beta is the key to cure long COVID
Dudio, I recommend you watch this Dr. John Campbell video about the SNG001 Phase 2 trial
https://www.youtube.com/watch?v=wqDd7ixh184
I'm Sorry let me be more clear.
I mean is it possible that they use diffident broker/ companies, each hold less then 3%, or less than 5% if they are for oversea. And together hold a very large %, like 30% or even 50% of SNG.
I kept thinking about the lack of TR1, and also the very large buying happened everyday over the last few weeks after the placing.
I am thinking there is no way with 80M placing, their and no TR1.
Is it possible that a big pharma is buying a lot of shares secretly, trying to take average of a take over. I am not a very experienced investor/trader, can someone tell me will they able to do that?
Also, let say if a big pharma is holding let say 30% or 50% of SNG shares. Will they then able to take over with a very low price, because they will have more vote.
Or maybe they are just simply thinking they can pay less to take over, because they already holding let say 30%, they just have to pay the high price for 70% shares.
I hope you guys understand what I am trying to ask, and sorry for my poor English.
Two incorrect thing in this article,
i.) but more recently Synairgen has published the results of a small pilot study suggesting that given in patients with milder disease – and inhaled rather than injected under the skin – it enhanced recovery.
-----It is given to hospitalised patients, not with milder disease .
ii.) Synairgen is now testing whether interferon-beta can prevent hospitalisation in patients who inhale it soon after testing positive, at home.
-----It is given in patients with milder disease, not to hospitalised patients,.
Well, NIH ACTIV-2 is an amalgamation of various departments including operation warp speed.
take a look at this.
https://www.nih.gov/research-training/medical-research-initiatives/activ
''On April 17, 2020 the National Institutes of Health (NIH) announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines.
Coordinated by the Foundation for the National Institutes of Health (FNIH), ACTIV brings NIH together with its sibling agencies in the Department of Health and Human Services, including the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA); other government agencies including the Department of Defense (DOD) and Department of Veterans Affairs (VA); Operation Warp Speed (OWS); the European Medicines Agency (EMA); and representatives from academia, philanthropic organizations, and numerous biopharmaceutical companies.''